Payment overview · 2025
General Payments
$30.14
1 reported records · 1 companies
Healthcare provider profile · identity verified
Lauren Ellis
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · LIMA, PA · NPI 1043661325
Verified facts
What the public records show
CMS Open Payments records show Lauren Ellis received $30.14 in general payments during 2025 across 1 reported records.
Lundbeck LLC accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $30.14 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $30.14 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $30.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Quetiapine Fumarate | Quetiapine Fumarate | 464 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 424 | 49 |
| Atorvastatin Calcium | Atorvastatin Calcium | 383 | 38 |
| Trazodone Hcl | Trazodone Hcl | 342 | 51 |
| Lorazepam | Lorazepam | 278 | 52 |
| Furosemide | Furosemide | 271 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 261 | 27 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 26 |
| Mirtazapine | Mirtazapine | 242 | 37 |
| Amlodipine Besylate | Amlodipine Besylate | 201 | 23 |
| Sertraline Hcl | Sertraline Hcl | 187 | 26 |
| Donepezil Hcl | Donepezil Hcl | 176 | 17 |
| Clonazepam | Clonazepam | 165 | 23 |
| Gabapentin | Gabapentin | 146 | 20 |
| Olanzapine | Olanzapine | 146 | 17 |
| Memantine Hcl | Memantine Hcl | 136 | 15 |
| Eliquis | Apixaban | 134 | 14 |
| Risperidone | Risperidone | 134 | 13 |
| Famotidine | Famotidine | 132 | 18 |
| Alprazolam | Alprazolam | 125 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 118 | 13 |
| Metformin Hcl | Metformin Hcl | 108 | 14 |
| Lisinopril | Lisinopril | 102 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 84 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 11 |
| Levetiracetam | Levetiracetam | 82 | suppressed |
| Bupropion Xl | Bupropion Hcl | 81 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 78 | suppressed |
| Erythromycin | Erythromycin Base | 76 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 76 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 74 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 71 | suppressed |
| Potassium Chloride | Potassium Chloride | 70 | 13 |
| Latanoprost | Latanoprost | 65 | 11 |
| Losartan Potassium | Losartan Potassium | 65 | suppressed |
| Baclofen | Baclofen | 64 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 63 | suppressed |
| Prednisone | Prednisone | 63 | 28 |
| Aripiprazole | Aripiprazole | 60 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 59 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | suppressed |
| Omeprazole | Omeprazole | 58 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 58 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 58 | suppressed |
| Restasis | Cyclosporine | 57 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 34 |
| Lamotrigine | Lamotrigine | 53 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 41 | 21 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Linzess | Linaclotide | 39 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 38 | suppressed |
| Haloperidol | Haloperidol | 38 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 38 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 38 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Myrbetriq | Mirabegron | 37 | suppressed |
| Simvastatin | Simvastatin | 37 | suppressed |
| Mupirocin | Mupirocin | 36 | 14 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 36 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 34 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Primidone | Primidone | 33 | suppressed |
| Carvedilol | Carvedilol | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 18 |
| Gemtesa | Vibegron | 30 | suppressed |
| Loperamide | Loperamide Hcl | 30 | 12 |
| Clozapine | Clozapine | 29 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 28 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 27 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 26 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 25 | suppressed |
| Nystatin | Nystatin | 25 | 11 |
| Phenobarbital | Phenobarbital | 25 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 25 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 25 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 24 | suppressed |
| Bumetanide | Bumetanide | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 22 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 18 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | suppressed |
| Paliperidone Er | Paliperidone | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 15 | suppressed |
| Lamotrigine Er | Lamotrigine | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | 11 |
| Pilocarpine Hcl | Pilocarpine Hcl | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 13 | suppressed |
| Olanzapine Odt | Olanzapine | 13 | suppressed |
| Pentoxifylline | Pentoxifylline | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Aplenzin | Bupropion Hbr | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Caplyta | Lumateperone Tosylate | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Levofloxacin | Levofloxacin | 12 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $30.14 · 1 records | Lundbeck LLC | REXULTI | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error